Curnutte John T

SEC source: 0001746473-26-000101 · wk-form4_1781298064.xml · derivative · entry 1

Curnutte John T · CIK 0001574589 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2036-06-11

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

SEC source: 0001746473-25-000129 · wk-form4_1749516237.xml · derivative · entry 1

Curnutte John T · CIK 0001574589 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-06-05

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

SEC source: 0001746473-24-000100 · wk-form4_1718669702.xml · derivative · entry 1

Curnutte John T · CIK 0001574589 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,764

Underlying: Common Stock · 26,764 shares

Expires 2034-06-13

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 13th, 2024 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 13, 2024 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

SEC source: 0000950170-24-007052 · ownership.xml · derivative · entry 2

Curnutte John T · CIK 0001574589 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 105,000 shares

Expires 2033-06-13

F1 · kind: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.

F2 · derivative.exercise_date: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration ($1.60 per share) over the per share exercise price of such options, and (ii) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares.

SEC source: 0000950170-24-007052 · ownership.xml · derivative · entry 1

Curnutte John T · CIK 0001574589 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 46,000 shares

Expires 2032-06-06

F1 · kind: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.

F2 · derivative.exercise_date: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration ($1.60 per share) over the per share exercise price of such options, and (ii) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares.

SEC source: 0001209191-23-037906 · doc4.xml · derivative · entry 1

Curnutte John T · CIK 0001574589 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Ordinary Shares · 105,000 shares

Expires 2033-06-13

F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 14, 2024 or the date of the 2024 Annual General Meeting of the Company.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares.

SEC source: 0001209191-23-035529 · doc4.xml · derivative · entry 1

Curnutte John T · CIK 0001574589 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 7th, 2023 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 7th, 2023 grant date, or (ii) the 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

SEC source: 0001567619-22-013194 · doc1.xml · derivative · entry 1

Curnutte John T · CIK 0001574589 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-06-15

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters beginning October 1st and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 16, 2022 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting.

SEC source: 0001209191-22-035006 · doc4.xml · derivative · entry 1

Curnutte John T · CIK 0001574589 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,000

Underlying: Ordinary Shares · 46,000 shares

Expires 2032-06-06

F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 7, 2023 or the date of the 2023 Annual General Meeting of the Company.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

SEC source: 0001209191-21-044172 · doc4.xml · derivative · entry 1

Curnutte John T · CIK 0001574589 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,286

Underlying: Common Stock · 13,286 shares

Expires 2031-06-28

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting.

SEC source: 0001209191-21-041499 · doc4.xml · derivative · entry 1

Curnutte John T · CIK 0001574589 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Ordinary Shares · 40,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 16, 2022 or the date of the 2022 Annual General Meeting of the Company.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

SEC source: 0001209191-20-037907 · doc4.xml · derivative · entry 1

Curnutte John T · CIK 0001574589 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Ordinary Shares · 35,000 shares

Expires 2030-06-16

F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 17, 2021 or the date of the 2021 Annual General Meeting of the Company.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

SEC source: 0001209191-19-031875 · doc4.xml · nonDerivative · entry 4

Curnutte John T · CIK 0001574589 · EVP R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,656

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

SEC source: 0001209191-19-031875 · doc4.xml · nonDerivative · entry 3

Curnutte John T · CIK 0001574589 · EVP R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,559

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

SEC source: 0001209191-19-031875 · doc4.xml · derivative · entry 5

Curnutte John T · CIK 0001574589 · EVP R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,688 shares

Expires 2027-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Performance Stock Unit (PSU) granted January 30, 2017 represented a contingent right to receive one (1) share of Issuer's Common Stock. 4,688 would have vested upon the one year anniversary of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018 but vesting was accelerated under the Reporting Person's Enhanced Severance Agreement upon Reporting Person's retirement and approval of the accelateration.

F1 · derivative.exercise_date: Each Performance Stock Unit (PSU) granted January 30, 2017 represented a contingent right to receive one (1) share of Issuer's Common Stock. 4,688 would have vested upon the one year anniversary of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018 but vesting was accelerated under the Reporting Person's Enhanced Severance Agreement upon Reporting Person's retirement and approval of the accelateration.

SEC source: 0001209191-19-031875 · doc4.xml · nonDerivative · entry 2

Curnutte John T · CIK 0001574589 · EVP R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,977

F2 · shares: Each Performance Stock Unit (PSU) granted March 29, 2018 represented a contingent right to receive one (1) share of Issuer's Common Stock. 1,750 would have vested upon the one year anniversary of the Compensation Committee's certification of the FDA's December 31, 2018 approval of Andexxa Gen 2 in the United States but vesting was accelerated under the Reporting Person's Enhanced Severance Agreement upon Reporting Person's retirement and approval of the acceleration.

SEC source: 0001209191-19-031875 · doc4.xml · nonDerivative · entry 1

Curnutte John T · CIK 0001574589 · EVP R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,227

F1 · shares: Each Performance Stock Unit (PSU) granted January 30, 2017 represented a contingent right to receive one (1) share of Issuer's Common Stock. 4,688 would have vested upon the one year anniversary of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018 but vesting was accelerated under the Reporting Person's Enhanced Severance Agreement upon Reporting Person's retirement and approval of the accelateration.

SEC source: 0001209191-19-016927 · doc4.xml · nonDerivative · entry 1

Curnutte John T · CIK 0001574589 · EVP R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,539

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

SEC source: 0001209191-19-006902 · doc4.xml · derivative · entry 2

Curnutte John T · CIK 0001574589 · EVP R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2029-01-30

F2 · derivative.exercise_date: The options shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 31, 2019, subject to the Reporting Person's Continuous Service as of each such date.

SEC source: 0001209191-19-006902 · doc4.xml · nonDerivative · entry 1

Curnutte John T · CIK 0001574589 · EVP R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,985

F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs vest in three equal annual installments on January 31, 2020, January 31, 2021 and January 31, 2022, subject to Reporting Person's Continuous Service under the Issuer's plan documents as of each such date.

SEC source: 0001209191-19-003820 · doc4.xml · nonDerivative · entry 2

Curnutte John T · CIK 0001574589 · EVP R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,485

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

SEC source: 0001209191-19-003820 · doc4.xml · nonDerivative · entry 1

Curnutte John T · CIK 0001574589 · EVP R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,200

F1 · shares: Each Performance Stock Unit ("PSU") granted March 29, 2018 represented a contingent right to receive one share of Issuer's Common Stock. 1,750 PSUs vested upon on January 12, 2019 certification by the Issuer's Compensation Committee of the FDA's December 31, 2018 approval of Andexxa Gen 2 in the United States. An additional 1,750 PSUs will vest on the first anniversary of the Certification Date.

SEC source: 0001209191-18-049647 · doc4.xml · nonDerivative · entry 2

Curnutte John T · CIK 0001574589 · Interim Co-President & EVP R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,200

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

SEC source: 0001209191-18-049647 · doc4.xml · nonDerivative · entry 1

Curnutte John T · CIK 0001574589 · Interim Co-President & EVP R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,084

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Each Performance Stock Unit ("PSU") granted on January 27, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 50% of the PSUs vested on July 28, 2018 and 50% vested on August 31, 2018.

SEC source: 0001209191-18-048722 · doc4.xml · nonDerivative · entry 2

Curnutte John T · CIK 0001574589 · Interim Co-President & EVP R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,084

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

SEC source: 0001209191-18-048722 · doc4.xml · nonDerivative · entry 1

Curnutte John T · CIK 0001574589 · Interim Co-President & EVP R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,255

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Each Performance Stock Unit ("PSU") granted on January 27, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 50% of the PSUs vested on July 28, 2018 and 50% will vest on August 31, 2018.

SEC source: 0001209191-18-033230 · doc4.xml · nonDerivative · entry 2

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,255

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

SEC source: 0001209191-18-033230 · doc4.xml · nonDerivative · entry 1

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,902

F1 · shares: Each Performance Stock Unit ("PSU") granted January 30, 2017 represented a contingent right to receive one share of Issuer's Common Stock. 4,687 PSUs became vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018. 4,688 PSUs will vest on the first anniversary of the Certification Date.

SEC source: 0001209191-18-019703 · doc4.xml · derivative · entry 2

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,049 shares

Expires 2021-03-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-019703 · doc4.xml · nonDerivative · entry 1

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,049

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-017393 · doc4.xml · nonDerivative · entry 1

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,499

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

SEC source: 0001209191-18-007229 · doc4.xml · derivative · entry 2

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2028-01-30

F2 · derivative.exercise_date: The option shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 1, 2018, subject to the Reporting Person's Continuous Service as of each such date.

SEC source: 0001209191-18-007229 · doc4.xml · nonDerivative · entry 1

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,750

F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2018, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-17-054452 · doc4.xml · derivative · entry 4

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,285 shares

Expires 2022-03-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-054452 · doc4.xml · derivative · entry 3

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,049

Underlying: Common Stock · 6,715 shares

Expires 2021-03-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-054452 · doc4.xml · nonDerivative · entry 2

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,285

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-054452 · doc4.xml · nonDerivative · entry 1

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,715

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-049637 · doc4.xml · nonDerivative · entry 1

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

SEC source: 0001209191-17-045853 · doc4.xml · derivative · entry 3

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,918

Underlying: Common Stock · 10,000 shares

Expires 2021-03-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.

SEC source: 0001209191-17-045853 · doc4.xml · nonDerivative · entry 2

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.

SEC source: 0001209191-17-045853 · doc4.xml · nonDerivative · entry 1

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.

SEC source: 0001209191-17-042166 · doc4.xml · derivative · entry 8

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,918

Underlying: Common Stock · 60,000 shares

Expires 2021-03-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.

SEC source: 0001209191-17-042166 · doc4.xml · nonDerivative · entry 7

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.

SEC source: 0001209191-17-042166 · doc4.xml · nonDerivative · entry 6

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.96, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4.

F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.

SEC source: 0001209191-17-042166 · doc4.xml · nonDerivative · entry 5

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,802

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.97, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4.

F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.

SEC source: 0001209191-17-042166 · doc4.xml · nonDerivative · entry 4

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,756

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.00 to $57.96, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4.

F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.

SEC source: 0001209191-17-042166 · doc4.xml · nonDerivative · entry 3

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,485

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.00 to $56.99, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4.

F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.

SEC source: 0001209191-17-042166 · doc4.xml · nonDerivative · entry 2

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,841

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.98 to $55.94, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4.

F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.

SEC source: 0001209191-17-042166 · doc4.xml · nonDerivative · entry 1

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.

SEC source: 0001209191-17-017787 · doc4.xml · nonDerivative · entry 1

Curnutte John T · CIK 0001574589 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,152

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).